In vivo proteomic imaging analysis of caveolae reveals pumping system to penetrate solid tumors

Nature Medicine

Volumn 20, Issue 9, 2014, Pages 1062-1068

  Oh, Phil ^a,b   Testa, Jacqueline E ^a,b   Borgstrom, Per ^b,c   Witkiewicz, Halina ^a,b   Li, Yan ^a,b   Schnitzer, Jan E ^a,b  

^a Proteogenomics Research Institute for Systems Medicine   (United States)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c Vaccine Research Institute of San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; CAVEOLA; HUMAN; IMAGE PROCESSING; METABOLISM; METHODOLOGY; NEOPLASM; PROTEOMICS;

ANIMALS; CAVEOLAE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEOPLASMS; PROTEOMICS;

EID: 84908332621     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3623     Document Type: Article

References (43)

1. Dvorak, H.F., Nagy, J.A. & Dvorak, A.M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3, 77-85 (1991).
2. Greish, K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target. 15, 457-464 (2007).
3. Hait, W.N. & Hambley, T.W. Targeted cancer therapeutics. Cancer Res. 69, 1263-1267, discussion 1267 (2009).
4. Jain, R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 4, 655-657 (1998).
5. Weissleder, R. & Pittet, M.J. Imaging in the era of molecular oncology. Nature 452, 580-589 (2008).
6. Willmann, J.K., van Bruggen, N., Dinkelborg, L.M. & Gambhir, S.S. Molecular imaging in drug development. Nat. Rev. Drug Discov. 7, 591-607 (2008).
7. Nie, S., Xing, Y., Kim, G.J. & Simons, J.W. Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng. 9, 257-288 (2007).
8. Schnitzer, J.E. Vascular targeting as a strategy for cancer therapy. N. Engl. J. Med. 339, 472-474 (1998).
9. Sugahara, K.N. et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031-1035 (2010).
10. Hajitou, A., Pasqualini, R. & Arap, W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc. Med. 16, 80-88 (2006).
11. Carver, L.A. & Schnitzer, J.E. in Endothelial Biomedicine (ed. Aird, W.C.) 664-678, 881-898 (Cambridge University Press, 2007).
12. Durr, E. et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat. Biotechnol. 22, 985-992 (2004).
13. Huang, X. et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275, 547-550 (1997).
14. Li, Y. et al. Enhancing identifications of lipid-embedded proteins by mass spectrometry for improved mapping of endothelial plasma membranes in vivo. Mol. Cell. Proteomics 8, 1219-1235 (2009).
15. Oh, P. et al. Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 25, 327-337 (2007).
16. Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629-635 (2004).
17. Oh, P., McIntosh, D.P. & Schnitzer, J.E. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol. 141, 101-114 (1998).
18. Schnitzer, J.E., Liu, J. & Oh, P. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J. Biol. Chem. 270, 14399-14404 (1995).
19. Schnitzer, J.E., McIntosh, D.P., Dvorak, A.M., Liu, J. & Oh, P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 269, 1435-1439 (1995).
20. Schnitzer, J.E., Oh, P. & McIntosh, D.P. Role of GTP hydrolysis in fission of caveolae directly from plasma membranes. Science 274, 239-242 (1996).
21. McIntosh, D.P., Tan, X.-Y., Oh, P. & Schnitzer, J.E. Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc. Natl. Acad. Sci. USA 99, 1996-2001 (2002).
22. Valadon, P. et al. Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo. J. Biol. Chem. 285, 713-722 (2010).
23. Dvorak, H.F., Nagy, J.A., Dvorak, J.T. & Dvorak, A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95-109 (1988).
24. Abell, R.G. The permeability of blood capillary sprouts and newly formed blood capillaries as compared to that of older blood capillaries. Am. J. Physiol. 147, 237-241 (1946).
25. Hobson, B. & Denekamp, J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer 49, 405-413 (1984).
26. Lindsay, M.A. Target discovery. Nat. Rev. Drug Discov. 2, 831-838 (2003).
27. Dalton, W.S. & Friend, S.H. Cancer biomarkers-an invitation to the table. Science 312, 1165-1168 (2006).
28. Hanash, S. & Taguchi, A. The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer 10, 652-660 (2010).
29. Huber, L.A. Is proteomics heading in the wrong direction? Nat. Rev. Mol. Cell Biol. 4, 74-80 (2003).
30. Stratton, M.R., Campbell, P.J. & Futreal, P.A. The cancer genome. Nature 458, 719-724 (2009).
31. Oh, P., Carver, L.A. & Schnitzer, J.E. in Cell Biology: A Laboratory Handbook 3rd edn. (ed. Celis, J.E.) 11-26 (Elsevier, Amsterdam, 2006).
32. Borgstrom, P. et al. Co-implanting orthotopic tissue creates stroma microenvironment enhancing growth and angiogenesis of multiple tumors. F1000Res. 2, 129 (2013).
33. Drab, M. et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293, 2449-2452 (2001).
34. Hannon, R. et al. Aberrant inflammation and resistance to glucocorticoids in annexin 1?/? mouse. FASEB J. 17, 253-255 (2003).
35. Yi, M. & Schnitzer, J.E. Impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1-null mice. Proc. Natl. Acad. Sci. USA 106, 17886-17891 (2009).
36. Haigler, H.T., Schlaepfer, D.D. & Burgess, W.H. Characterization of lipocortin I and an immunologically unrelated 33-kDa protein as epidermal growth factor receptor/kinase substrates and phospholipase A2 inhibitors. J. Biol. Chem. 262, 6921-6930 (1987).
37. Wang, W. & Creutz, C.E. Role of the amino-terminal domain in regulating interactions of annexin I with membranes: effects of amino-terminal truncation and mutagenesis of the phosphorylation sites. Biochemistry 33, 275-282 (1994).
38. Aird, W.C. et al. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J. Cell Biol. 138, 1117-1124 (1997).
39. Schnitzer, J.E., Carley, W.W. & Palade, G.E. Specific albumin binding to microvascular endothelium in culture. Am. J. Physiol. 254, H425-H437 (1988).
40. Testa, J.E. et al. Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L251-L262 (2009).
41. Testa, J.E., Chrastina, A., Li, Y., Oh, P. & Schnitzer, J.E. Ubiquitous yet distinct expression of podocalyxin on vascular surfaces in normal and tumor tissues in the rat. J. Vasc. Res. 46, 311-324 (2009).
42. Oh, P. & Schnitzer, J.E. Immunoisolation of caveolae with high affinity antibody binding to the oligomeric caveolin cage. Toward understanding the basis of purification. J. Biol. Chem. 274, 23144-23154 (1999).
43. Harlow, E. & Lane, D. in Antibodies: A Laboratory Manual (Cold Spring Harbor Press, Cold Spring Harbor, New York, 1998).